2022年4月12日

肯·基爾博士加入Melior科學業務副總裁李支博士加入Melior腫瘤學主任維維安Cong上升到博士研發副總裁4月12日,2022年東部時間上午喂飼EXTON, Pa。——(業務線)——Melior發現,Inc . (Melior)今天宣布顯著的增加了它的管理組織。加入Melior組織將肯·基爾博士(博士、MBA)作為藥理學的副總裁。李也加入Melior博士將支腫瘤學主任。此外,Melior老兵,維維安琮、博士將上升到研究和開發的副總裁的角色。祈戈是15年來行業資深博士已經開始他的職業生涯在輝瑞製藥行業在繼續葛蘭素史克然後詹森之前,他獲得的早期概念驗證的導演團隊水平免疫學。2020年,他離開詹森,成為投資首席科學官腹腔以外的組織。整個跨度·基爾博士的職業生涯奉獻自己的體內藥理學家治療領域包括炎症、免疫學、疼痛以及肺學。李博士一直練習體內藥理學家三十多年了,在美國國立衛生研究院(貝塞斯達)4年研究員研究維生素C在各種癌症治療之前紀念斯隆-凱特琳癌症中心。她上升到水平的研究助理,她負責管理斯隆為癌症動物模型的核心設備。在這種能力,她的設計和執行研究異種移植和syngenic腫瘤模型,包括patient-derived異種移植(PDX)模型,與一係列治療方法包括嵌合抗原受體t細胞(CAR-T)療法。 Prior to joining Melior six years ago Dr. Cong dedicated her studies to preclinical in vivo pharmacology research in the areas on metabolic disease and neurodegeneration in research institutions including the National Institute of Health (Bethesda) and The Hospital for Sick Children (Toronto). Over the years that she has been at Melior Dr. Cong has taken on increasing responsibility, developing new animal models in new therapeutic areas and thereby expanding Melior’s repertoire and capability across broad therapeutic area space. Today, Dr. Cong has different levels of involvement in all models that are performed at Melior. More detailed biographical information on these individuals can be found on Melior’s website . “I am proud of the fact that in this very challenging hiring market, Melior has been able to attract not only these very talented senior veterans that bring such a wealth of capability and knowledge to Melior, but also an array of talented more junior people as well,” said Andrew Reaume, president and CEO of Melior. “It's a testimony to the vibrant and fulfilling environment that we have developed here as well as a demonstration of quantum growth that Melior is experiencing.” About Melior Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE® platform comprised of multiplexed in vivo disease models. Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the theraTRACE® platform and its in-depth in vivo pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com . Contacts